Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …

Human mucosal-associated invariant T (MAIT) cells are characterized by their expression of
an invariant TCR α chain Vα7. 2-Jα33/Jα20/Jα12 paired with a restricted TCR β chain. MAIT …

Advances in the design of chimeric antigen receptors (CARs) have improved the antitumor
efficacy of redirected T cells. However, functional heterogeneity of CAR T cells limits their …

Chimeric antigen receptor (CAR)-engineered T-cell (CAR-T) therapy has demonstrated
impressive therapeutic efficacy against hematological malignancies, but multiple challenges …

Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse
complications of allogeneic transplantation which still cause substantial morbidity and …

NK1. 1 and its human homolog CD161 are expressed on NK cells, subsets of CD4+ and
CD8+ T cells, and NKT cells. While the expression of NK1. 1 is thought to be inhibitory to NK …

NKT cells are a relatively newly recognized member of the immune community, with
profound effects on the rest of the immune system despite their small numbers. They are true …

iNKT cells are a subset of innate-like T cells that utilize an invariant TCR alpha chain
complexed with a limited repertoire of TCR beta chains to recognize specific lipid antigens …

Vα24-invariant natural killer T cells (NKTs) localize to tumors and have inherent antitumor
properties, making them attractive chimeric antigen receptor (CAR) carriers for redirected …

Natural killer T (NKT) cells are innate-like lymphocytes that generally recognize lipid
antigens and are enriched in microvascular compartments of the liver. NKT cells can be …